15,632 Shares in Sanofi $SNY Purchased by Runnymede Capital Advisors Inc.

Runnymede Capital Advisors Inc. purchased a new position in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,632 shares of the company’s stock, valued at approximately $758,000.

A number of other institutional investors also recently bought and sold shares of the company. Sowell Financial Services LLC raised its stake in Sanofi by 61.7% during the fourth quarter. Sowell Financial Services LLC now owns 8,480 shares of the company’s stock worth $411,000 after purchasing an additional 3,237 shares during the period. Florida Trust Wealth Management Co purchased a new position in Sanofi during the fourth quarter worth about $245,000. Signaturefd LLC raised its stake in Sanofi by 3.2% during the fourth quarter. Signaturefd LLC now owns 34,200 shares of the company’s stock worth $1,657,000 after purchasing an additional 1,067 shares during the period. Perigon Wealth Management LLC raised its stake in Sanofi by 12.2% during the fourth quarter. Perigon Wealth Management LLC now owns 6,172 shares of the company’s stock worth $299,000 after purchasing an additional 671 shares during the period. Finally, Aberdeen Group plc raised its stake in Sanofi by 22.7% during the fourth quarter. Aberdeen Group plc now owns 467,241 shares of the company’s stock worth $22,642,000 after purchasing an additional 86,314 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on SNY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Weiss Ratings downgraded shares of Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, March 23rd. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Sanofi has a consensus rating of “Hold” and a consensus price target of $61.50.

Sanofi Price Performance

Sanofi stock opened at $47.14 on Thursday. The company’s 50 day simple moving average is $46.46 and its 200-day simple moving average is $48.01. The company has a market capitalization of $114.97 billion, a price-to-earnings ratio of 13.09, a price-to-earnings-growth ratio of 1.19 and a beta of 0.42. Sanofi has a 1 year low of $43.32 and a 1 year high of $55.73. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.